Apollo Endosurgery, Inc. (APEN): Price and Financial Metrics

Apollo Endosurgery, Inc. (APEN)

Today's Latest Price: $1.80 USD

0.13 (7.78%)

Updated Jun 4 4:00pm

Add APEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

APEN Stock Summary

  • Apollo Endosurgery Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 1.95% of US listed stocks.
  • APEN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 95.81% of US stocks.
  • Apollo Endosurgery Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -51.28%, greater than the shareholder yield of merely 8.31% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Apollo Endosurgery Inc, a group of peers worth examining would be ALIM, QTT, ADMS, CMPR, and NLST.
  • Visit APEN's SEC page to see the company's official filings. To visit the company's web site, go to www.apolloendo.com.
APEN Daily Price Range
APEN 52-Week Price Range

APEN Stock Price Chart More Charts

APEN Price/Volume Stats

Current price $1.80 52-week high $3.94
Prev. close $1.67 52-week low $1.24
Day low $1.67 Volume 61,694
Day high $1.80 Avg. volume 13,108
50-day MA $2.08 Dividend yield N/A
200-day MA $2.71 Market Cap 38.03M

Apollo Endosurgery, Inc. (APEN) Company Bio

Apollo Endosurgery, Inc. focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company is based in Austin, Texas.

APEN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

APEN Latest Social Stream

Loading social stream, please wait...

View Full APEN Social Stream

Latest APEN News From Around the Web

Below are the latest news stories about Apollo Endosurgery Inc that investors may wish to consider to help them evaluate APEN as an investment opportunity.

Apollo Endosurgery, Inc. Reports First Quarter 2020 Results

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / May 4, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive ...

Yahoo | May 4, 2020

Apollo Endosurgery, Inc. to Report First Quarter 2020 Results on May 4, 2020

AUSTIN, TX / ACCESSWIRE / April 30, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today ...

Yahoo | April 30, 2020

Analysis of COVID-19-Global Intragastric Balloons Market 2020-2024 | Evolving Opportunities with Allurion Technologies Inc. and Apollo Endosurgery Inc. | Technavio

LONDON--(BUSINESS WIRE)-- #IntragastricBalloonsMarket--The intragastric balloons market size has the potential to grow by USD 144.87 million during 2020-2024

Business Wire | April 15, 2020

Apollo Endosurgery Announces Completion of the US Post-Approval Study for the Orbera(R) Intragastric Balloon System

AUSTIN, TX / ACCESSWIRE / April 13, 2020 / Apollo Endosurgery, Inc. ("Apollo") (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced today that the US Food and Drug Administration (FDA) has completed the review of the final Post-Approval Study (PAS) Report for the Orbera Intragastric Balloon System and accepted that all post-approval study requirements have been fulfilled. The ORBERA Post Approval Study was a requirement following the US FDA's approval of ORBERA in August of 2015.

Yahoo | April 13, 2020

Analysts Just Slashed Their Apollo Endosurgery, Inc. (NASDAQ:APEN) EPS Numbers By 15%

One thing we could say about the analysts on Apollo Endosurgery, Inc. (NASDAQ:APEN) - they aren't optimistic, having...

Yahoo | March 31, 2020

Read More 'APEN' Stories Here

APEN Price Returns

1-mo -0.55%
3-mo -28.57%
6-mo -33.33%
1-year -50.68%
3-year -72.89%
5-year -91.94%
YTD -36.84%
2019 -17.39%
2018 -38.39%
2017 -53.95%
2016 -31.34%
2015 -91.84%

Continue Researching APEN

Want to see what other sources are saying about Apollo Endosurgery Inc's financials and stock price? Try the links below:

Apollo Endosurgery Inc (APEN) Stock Price | Nasdaq
Apollo Endosurgery Inc (APEN) Stock Quote, History and News - Yahoo Finance
Apollo Endosurgery Inc (APEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9027 seconds.